The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial

BACKGROUND: Tuberous Sclerosis Complex (TSC) is a genetic disorder characterised by the development of benign tumours secondary to loss of inhibitory regulation of the mTOR (mechanistic Target of Rapamycin) intracellular growth pathway. Metformin inhibits the mTOR pathway. We investigated whether me...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EClinicalMedicine
Autori principali: Amin, Sam, Mallick, Andrew A, Edwards, Hannah, Cortina-Borja, Mario, Laugharne, Matthew, Likeman, Marcus, O'Callaghan, Finbar J.K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7910694/
https://ncbi.nlm.nih.gov/pubmed/33681737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100715
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi